RELMADA THERAPEUTICS, INC. Logo

RELMADA THERAPEUTICS, INC.

Clinical-stage biotech developing therapies for bladder cancer and compulsive disorders.

RLMD | US

Overview

Corporate Details

ISIN(s):
US75954H1005 (+1 more)
LEI:
Country:
United States of America
Address:
2222 PONCE DE LEON BLVD. 3RD FLOOR, 33134 CORAL GABLES

Description

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-16 15:30 English ZIP 7.6 KB
2025-12-16 15:30 English ZIP 7.2 KB
2025-12-16 15:30 English ZIP 7.0 KB
2025-12-16 15:29 English ZIP 6.9 KB
2025-12-16 15:29 English ZIP 7.0 KB
2025-12-16 15:28 English ZIP 7.0 KB
2025-12-16 15:28 English ZIP 7.0 KB
2025-12-15 13:50
CURRENT REPORT
English ZIP 356.0 KB
2025-11-15 00:28 English ZIP 211.6 KB
2025-11-13 22:58
CURRENT REPORT
English ZIP 8.4 MB
2025-11-13 22:07
QUARTERLY REPORT
English ZIP 888.0 KB
2025-11-06 13:30 English ZIP 6.6 KB
2025-11-06 13:30 English ZIP 6.6 KB
2025-11-06 13:30 English ZIP 6.6 KB
2025-11-06 13:30 English ZIP 6.6 KB

Automate Your Workflow. Get a real-time feed of all RELMADA THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RELMADA THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RELMADA THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

DG INNOVATE PLC Logo
Develops sustainable technologies for electric mobility and energy storage solutions.
United Kingdom
DGI
Dianthus Therapeutics, Inc. /DE/ Logo
Clinical-stage biotech developing therapies for severe autoimmune diseases.
United States of America
DNTH
Dogwood Therapeutics, Inc. Logo
A biotech company developing novel therapeutics for pain and neuropathy.
United States of America
DWTX
DreamCIS INC. Logo
Contract research organization for pharma, biotech, and medical device industries.
South Korea
223250
DT&CRO CO., Ltd. Logo
A full-service CRO providing non-clinical and clinical studies for various industries.
South Korea
383930
D.Western Therapeutics Institute, Inc. Logo
Biotechnology firm developing drugs from a proprietary protein kinase inhibitor library.
Japan
4576
Ectin Research AB Logo
Pharmaceutical company developing novel oncology treatments, with a lead drug in trials.
Sweden
ECTIN B
EdgeLab S.p.A. Logo
Designs and manufactures marine and underwater solutions, including AUVs and robotics.
Italy
ELB
Editas Medicine, Inc. Logo
A clinical-stage genome editing company developing CRISPR medicines for serious diseases.
United States of America
EDIT
Eledon Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing therapies for organ and autoimmune diseases.
United States of America
ELDN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.